Payment overview · 2025
General Payments
$47,913.28
40 reported records · 10 companies
Healthcare provider profile · identity verified
Tarun Wasil, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW HYDE PARK, NY · NPI 1710949862
Verified facts
What the public records show
CMS Open Payments records show Tarun Wasil, MD received $47,913.28 in general payments during 2025 across 40 reported records.
GlaxoSmithKline, LLC. accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence, Ojjaara, Sarclisa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Lupron Depot by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Calquence by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AYVAKIT as an associated drug or biological on 4791 records involving 3585 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ayvakit by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SARCLISA as an associated drug or biological on 7155 records involving 4028 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sarclisa by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ojjaara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RETEVMO as an associated drug or biological on 938 records involving 736 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Retevmo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16,827.26 | 35.1% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $9,082.50 | 19.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $5,206.67 | 10.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $5,018.89 | 10.5% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $3,099.81 | 6.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $2,550.00 | 5.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $2,466.82 | 5.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $1,645.00 | 3.4% | 1 | 2025 |
| B. Braun Medical Inc. | Unresolved — no canonical attribution shown | $1,156.33 | 2.4% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $860.00 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,032.50 | 14 |
| Consulting Fee | $13,442.50 | 8 |
| Travel and Lodging | $2,216.39 | 5 |
| Debt forgiveness | $1,156.33 | 1 |
| Food and Beverage | $1,065.56 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $15,667.97 | 8 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $9,082.50 | 6 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $3,068.00 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $2,550.00 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $1,725.00 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $1,645.00 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $1,645.00 | 1 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $550.00 | 2 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $31.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SARCLISA sarclisa |
2025 | Sarclisa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | AYVAKIT open payments reported associated product |
CMS Open Payments — General Payments 4791 supporting records · 3585 recipient NPIs · example record 1233194960 |
Ayvakit · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | SARCLISA open payments reported associated product |
CMS Open Payments — General Payments 7155 supporting records · 4028 recipient NPIs · example record 1233194888 |
Sarclisa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | RETEVMO open payments reported associated product |
CMS Open Payments — General Payments 938 supporting records · 736 recipient NPIs · example record 1186464845 |
Retevmo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Aranesp | Darbepoetin Alfa In Polysorbat | 125 | 24 |
| Akynzeo | Fosnetupitant/Palonosetron | 117 | 28 |
| Procrit | Epoetin Alfa | 101 | 19 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 88 | suppressed |
| Anastrozole | Anastrozole | 73 | 24 |
| Eliquis | Apixaban | 55 | 15 |
| Xgeva | Denosumab | 55 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 32 |
| Acyclovir | Acyclovir | 49 | 12 |
| Allopurinol | Allopurinol | 47 | 19 |
| Prednisone | Prednisone | 47 | 11 |
| Revlimid | Lenalidomide | 46 | suppressed |
| Calquence | Acalabrutinib Maleate | 45 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 42 | suppressed |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 42 | suppressed |
| Kyprolis | Carfilzomib | 35 | suppressed |
| Neulasta | Pegfilgrastim | 33 | suppressed |
| Zarxio | Filgrastim-Sndz | 33 | suppressed |
| Pomalyst | Pomalidomide | 31 | suppressed |
| Neulasta Onpro | Pegfilgrastim | 28 | 11 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 26 | suppressed |
| Lupron Depot | Leuprolide Acetate | 26 | suppressed |
| Brukinsa | Zanubrutinib | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 14 |
| Prolia | Denosumab | 23 | 15 |
| Oxaliplatin | Oxaliplatin | 22 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 22 | suppressed |
| Hydroxyurea | Hydroxyurea | 21 | suppressed |
| Letrozole | Letrozole | 20 | suppressed |
| Ojjaara | Momelotinib Dihydrochloride | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Imatinib Mesylate | Imatinib Mesylate | 17 | suppressed |
| Azacitidine | Azacitidine | 15 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Deferasirox | Deferasirox | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Nubeqa | Darolutamide | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | 13 |
| Docetaxel | Docetaxel | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Tecentriq | Atezolizumab | 13 | suppressed |
| Erlotinib Hcl | Erlotinib Hcl | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lenalidomide | Lenalidomide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Orserdu | Elacestrant Hcl | 12 | suppressed |
| Ayvakit | Avapritinib | 11 | suppressed |
| Nplate | Romiplostim | 11 | suppressed |
| Promacta | Eltrombopag Olamine | 11 | suppressed |
| Retevmo | Selpercatinib | 11 | suppressed |
| Riabni | Rituximab-Arrx | 11 | suppressed |
| Sarclisa | Isatuximab-Irfc | 11 | suppressed |
| Thalomid | Thalidomide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47,913.28 · 40 records | GlaxoSmithKline, LLC. | CALQUENCE, ELREXFIO, JAYPIRCA, OJJAARA, SARCLISA, TALVEY, TECVAYLI, VENCLEXTA, WAYRILZ | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error